1. Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, Ohashi K, Nagane M, Narita Y, et al. Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies. Cancers (Basel). 2022;14(17).
2. Narita Y, Okita Y, Arakawa Y. Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma. Cancer Immunol Immunother. 2022.
3. Omura T, Takahashi M, Ohno M, Miyakita Y, Yanagisawa S, Tamura Y, Narita Y, et al. Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. Cancers (Basel). 2022;14(10).
4. Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Tamura Y, Narita Y. Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. Jpn J Clin Oncol. 2022;52(10):1134-42.
5. Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Tamura Y, Kawauchi D, Narita Y, et al. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma. Radiat Oncol. 2022;17(1):85.
6. Ohno M, Kitano S, Satomi K, Yoshida A, Miyakita Y, Takahashi M, Narita Y, et al. Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas. J Neurooncol. 2022.
7. Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Omura T, Narita Y, et al. Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma. Neurosurgery. 2022;91(5):741-8.
8. Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita Y, Takahashi M, Yanagisawa S, Narita Y, et al. The clinical characteristics and outcomes of incidentally discovered glioblastoma. J Neurooncol. 2022;156(3):551-7.
9. Hosoya T, Takahashi M, Honda-Kitahara M, Miyakita Y, Ohno M, Yanagisawa S, Narita Y, et al. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. J Neurooncol. 2022;157(3):561-71.
10. Hosoya T, Takahashi M, Ohno M, Davey C, Sese J, Honda-Kitahara M, Miyakita Y, Narita Y,et al. Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy. Biomolecules. 2022;12(10).